

Adult female acne can be an indication for Antiandrogen therapy

Bing Hao* and Munjal Mahto

Department of Dermatology, Northwick Park Hospital, London, United Kingdom

Corresponding Author

Bing Hao, Department of Dermatology, Northwick Park Hospital, London, United Kingdom,
E-mail: binghao@gmail.com

Received Date: Nov 22, 2021

Accepted Date: Nov 26, 2021

Published Date: Dec 28, 2021

Keywords

Acne, Androgens, Spironolactone, Cyproterone

Introduction

Acne vulgaris could be a complex sickness of the follicle unit as a result of androgen-induced enhanced secretion production, altered biological process, inflammation, and follicle microorganism settlement by *Propionibacterium acnes* (*P. acnes*) [1]. The clinical options of disease of the skin embrace skin disorder, comedones, and papules and pustules. Nodules and cysts square measure seen in severe nodulocystic disease of the skin and scarring will follow. disease of the skin will occur alone or with signs of hyperandrogenism like hirsuteness, baldness and discharge irregularity.

Acne vulgaris could be a common reason why adult ladies gift to dermatologists and may be a clinical challenge to treat. though disease of the skin is most typically related to adolescence [2], it usually persists into adulthood [3]. Perkins et al studies prevalence of disease of the skin in 2895 ladies and located over 1 / 4 had disease of the skin and though disease of the skin peaked in teens it continues to be rife through the fifth decade [4]. Adult disease of the skin regarding current androgens is commonly named as late-onset or post-adolescent disease of the skin [5]. disease of the skin will cause important psychological distress, that has been shown to boost with effective treatment [6].

Anti-androgen medical care is indicated for moderate to severe papulopustular/nodular disease of the skin in feminine patients resistant to initial line medical care or wherever hyperandrogenism is known [7]. though commonplace disease of the skin therapies are often with success accustomed treat disease of the skin in woman patients, anti-androgen treatment is a good therapeutic choice which will offer a chance to higher target disease of the skin during this population, even once alternative general therapies are unsuccessful. This review discusses non-contraceptive secretion medical care as well as cyproterone acetate, Aldactone and flutamide. Contraceptives with steroid activities and topical treatments square measure on the far side the scope of this review.

Pathogenesis

Androgens play a crucial role within the pathophysiology and treatment

of disease of the skin [8,9]. alternative vital factors square measure inflammatory mediators free into the skin, alteration of the method|biological process} process resulting in comedones, and cyst settlement by *P. acnes* [1]. there's no disease of the skin while not secretion, that is a nutrient supply for *P. acnes*, and androgens square measure the key sebotropic hormones [1].

Androgens in girls square measure derived from 3 sources: the ovaries, adrenal glands, and peripheral conversion. previous to time of life, the adrenal glands manufacture increasing amounts of dehydroepiandrosterone sulfate (DHEAS), that is metabolized into active androgens within the skin [4]. Androgens drive enlargement of the glandulae sebaceae and increase secretion production. inflated or altered secretion production beneath steroid management may be a important step within the formation of disease of the skin all told populations [10]. inflated sensitivity of the oil gland unit to androgens has additionally been recommended united reason for disease of the skin [11]. In skin, steroid receptors square measure placed in oily glands and within the outer root sheath of the follicle. Sebocytes and keratinocytes of the oil gland vesicle bodily structure in patients with disease of the skin have steroid receptors that square measure each a lot of varied and a lot of sensitive than those in traditional subjects.

Clinical observations reinforce the role of androgens in disease of the skin. Conditions of hyperandrogenism, like polycystic ovary syndrome (PCOS), square measure related to disease of the skin, that is very awake to anti- androgens [12]. moreover, rising levels of dehydroepiandrosterone sulphate (DHEA-S) square measure related to the onset of disease of the skin in pre- menarchal ladies, and better levels in pre-menarche might predict the event of a lot of clinically severe disease of the skin in time of life [13]. Elevated DHEA-S additionally correlates with clinical disease of the skin in an exceedingly set of patients with PCOS [14]. Fluctuations in androgens throughout the cycle might account for diurnal flares, together with the usually rumored expelling flares of disease of the skin.

Differential Diagnosis of disease of the skin in girls

A thorough case history and physical examination is important for assessment of feminine adults presenting with disease of the skin. The common medical diagnosis of woman disease of the skin includes: acne rosacea, seborrheic eczema, and hyperandrogenism (including PCOS). Signs and symptoms of hyperandrogenism embrace hairiness, alopecia, amenia or menstruation, and ontogenesis, as proved by deepening of the voice, clitoromegaly and inflated muscle mass. hairiness is that the commonest manifestation (70-80%) and is very related to elevated levels of free androgenic hormone [15].

The most common reason for hyperandrogenism is PCOS. The city agreement criteria outline designation of PCOS as 2 of the subsequent 3 criteria: amenia or menstruation, organic chemistry or clinical hyperandrogenism, and ultrasonographic documentation of inflated vesicle count (> 12) or vesicle volume (> ten cm³) per ovary. Dermatologists ought to be accustomed to the diagnostic work- from PCOS, that consists of assessment of endocrine (total and free androgenic hormone, FSH, LH, prolactin, 17-hydroxyprogesterone and DHEA) and metabolic parameters (fasting hormone and lipids).

An important differential to remember of is androgen-secreting tumours which might occur all told ages and gift with fast onset disease of the skin. High levels of androgenic hormone (> 150-200 ngdL-1) related

to traditional levels of DHEA square measure suggestive for sex gland growth. High levels of DHEA (> 8000 nanogram mL⁻¹) square measure suggestive for adrenal tumours. gently elevated levels of DHEA (4000-8000 nanogram mL⁻¹) square measure found in CAH, PCOS and Harvey Cushing sickness. High levels of 17-OHP and a positive corticotropin (ACTH) stimulation check square measure essential to form the designation of CAH [16].

Anti-Androgen Therapy

Anti-androgens square measure agents that inhibit directly the binding of dihydrotestosterone (DHT) to its receptor in a very competitive manner. They embrace cyproterone acetate (CPA), corticoid, and flutamide. All antiandrogens square measure contraindicated in men as a result of they end in pathologic process, and conjointly in ladies throughout maternity [17].

Cyproterone acetate

Cyproterone acetate may be a progestational anti-androgen artificial steroidal agent. It blocks the androgenic hormone receptor, specifically those sensitive to DHT [18]. accountant is that the solely anti-androgen that conjointly has anti-gonadotropin action and inhibits biological process [19]. it's used with Associate in Nursing steroid within the treatment of majority of skin problem cases like in combined oral contraceptives (COC) however it will be used alone. accountant inhibits the conversion of DHEA to androstenedione by 3-beta hydroxysteroid dehydrogenase, decreasing adrenal androgenic hormone production. accountant conjointly inhibits the assembly of gonadotropic hormone and gonadotropic hormone, that blocks gonad operate and reduces humour androgenic hormone levels. Treatment with anti-androgen conjointly scale back comedones indirectly by a rise of greasy linoleate concentration [18].

Treatment with accountant ought to begin on the primary or fifth day of the cycle and will be stopped on the fourteenth day simply before biological process [19]. once used alone, the suggested dose is fifty to a hundred mg daily. Studies have shown that Associate in Nursing overall improvement of skin problem in 75-90% of cases will be seen [20,21]. Side effects of accountant embrace discharge irregularities, breast tenderness, fluid retention, headache and nausea [22]. the foremost regarding aspect impact reported is liver toxicity, that is dose dependent [23]. the speed of discharge irregularities is considerably reduced once accountant is combined with Associate in Nursing steroid [19].

During the primary 10-15 days of the cycle, accountant at a dose of twelve.5-50 mg daily will be another to COC already containing accountant. This avoids discharge irregularities caused throughout treatment with accountant alone [22]. A recent review of the advantages and risks of co-cyprindiol following issues in France regarding the danger of blood vessel occlusion finished that the 'balance of advantages and risks remains positive' for treatment of skin conditions associated with androgenic hormone sensitivity like severe skin problem with or while not skin problem [24].

CPA is contraindicated in those with disease, malignancy (other than prostate cancer), history of tumour, severe polygenic disorder, hematologic disorders, and chronic severe depression. Patients on accountant ought to have liver operate observance.

Spironolactone

Spironolactone is Associate in Nursing mineralocorticoid antagonist. The mechanisms of action square measure as follows 1. Decrease the activity of 5-alpha enzyme via magnified clearance of androgen secondary to increased liver hydroxylase activity two. vie with dihydrotestosterone for androgenic hormone receptors and decreasing the number of secretion production stirred up by androgens three. scale back levels of

free androgen by increasing binding to hormone binding simple protein [25].

Spironolactone is well documented to be a good treatment for hormonally mediate skin problem [26-29]. it's been with success used

for feminine patients with skin problem, hairiness and phalacrosis for years [30]. In doses of fifty to a hundred mg once or doubly daily, loving meals, it's been shown to scale back secretion excretion rate by half-hour to five hundredth and improve skin problem [17,31,32]. Clinical improvement of skin problem is usually seen once three months and effective maintenance doses vary from twenty five to fifty mg daily.

However, the Cochrane review in 2009 considers there to be insufficient proof to be used of corticoid in skin problem thanks to restricted variety of trials and tiny sample size [33]. It ought to be reserved for medical aid- recalcitrant cases immune to typical therapy, and it's helpful in countries wherever alternative secretion treatments square measure contraindicated or untouchable [17].

Adverse effects square measure dose-dependent. Low doses of twenty five to fifty mg daily square measure typically well tolerated [17]. Common aspect effects embrace symptom, discharge irregularities, breast tenderness or enlargement, reduced concupiscence and hypercalcemia. These aspect effects square measure sometimes gentle in severity and a discount of the dose is decent to scale back them to acceptable levels. Irregular discharge hemorrhage Associate in Nursing alternative aspect effects square measure improved once corticoid is employed together with an steroid [17].

Spironolactone is employed as a K stinting drug Associate in Nursing symptom is an uncommon aspect impact. A recent retrospective study of 974 young ladies found the speed of symptom in healthy young ladies taking corticoid for skin problem is love the baseline rate of symptom during this population [34]. Routine observance of K isn't suggested however K supplementation and angiotensin-converting protein inhibitors ought to be avoided [34].

Spironolactone ought to be avoided in patients in danger of carcinoma or alternative steroid dependent malignancies. The potential for it to induce steroid dependent malignancies remains a arguable topic [35]. Treatment with corticoid throughout maternity is contraindicated (FDA maternity class C) and will result in abnormalities of the male craniate private parts, like abnormal condition [32].

Flutamide

Flutamide could be a non-steroidal androgenic hormone antagonist utilized in the management of prostate hypertrophy, prostatic adenocarcinoma, and hirsuteness. The anti-androgen activity is because of competitive inhibition of androgenic hormone receptors, particularly those that bind DHT. Flutamide additionally enhances androgens breakdown to inactive metabolites. Flutamide are often effective for the treatment of skin disease, hirsuteness and baldness [32]. It are often used alone or together with antidiabetic drug or COC in patients with PCOS.

Most irregular management trials on flutamide have targeted on hirsuteness. solely 2 irregular management trial known for this review specifically studied skin disease [36,37]. The trials compared the effectuality of flutamide with cyproterone-estradiol mixtures in treating skin disease. It found flutamide to be a minimum of as effective at treating skin disease however required any studies with larger sample sizes. Eight alternative studies were known that found a marked improvement in skin disease treated with flutamide compared with baseline or placebo [38-45].

Hepatic toxicity limits the utilization of flutamide. There ar cases of fatal liver disease reported [17,32]. Regular liver operate tests and watching is necessary if used. alternative major aspect effects ar gi disorders (diarrhea), muscle cramps and abnormalcy.

Flutamide is additionally contraindicated in maternity because it will

cross the placental barrier and causes feminisation of the male vertebrate [36].

Conclusion

Acne in feminine adult has vital psychosocial comorbidity and should be difficult to treat. within the latest European pointers anti-androgens are indicated as a treatment choice for severe papulopustular skin disease once combined with oral antibiotics or topical medical aid [46]. they're a secure and effective choice for woman patients with moderate to severe skin disease immune to 1st line treatment or with options of hyperandrogenism. Isotretinoin remains a extremely effective treatment choice during this patient population however anti- androgens like certified public accountant and corticoid offer a crucial choice even once alternative treatments have unsuccessful. it's tough to draw conclusions comparison the effectuality of various anti-androgens on the obtainable date. a lot of top quality studies into the advantages of anti- androgenic hormone therapies are required.

References

- Williams HC, Dellavalle RP, Garner S (2012) Acne vulgaris. *Lancet* 379: 361- 372.
- Law MP, Chuh AA, Lee A, Molinari N (2010) Acne prevalence and beyond: acne disability and its predictive factors among Chinese late adolescents in Hong Kong. *Clin Exp Dermatol* 35: 16-21.
- Collier CN, Harper JC, Cafardi JA, Cantrell WC, Wang W, et al. (2008) The prevalence of acne in adults 20 years and older. *J Am Acad Dermatol* 58: 56-59.
- Perkins AC, Maglione J, Hillebrand GG, Miyamoto K, Kimball AB (2012) Acne vulgaris in women: prevalence across the life span. *J Womens Health (Larchmt)* 21: 223-230.
- Seirafi H, Farnaghi F, Vasheghani-Farahani A, Alirezaie NS, Esfahanian F, et al. (2007) Assessment of androgens in women with adult-onset acne. *Int J Dermatol* 46: 1188-1191.
- Pagliarello C, Di Pietro C, Tabolli S (2015) A comprehensive health impact assessment and determinants of quality of life, health and psychological status in acne patients. *G Ital Dermatol Venereol* 150: 303-308.
- Bettoli V, Zauli S, Virgili A (2015) Is hormonal treatment still an option in acne today? *Bri J Dermatol* 172: 37-46.
- Suh DH, Kwon HH (2015) What's new in the physiopathology of acne? *Br J Dermatol* 172: 13-19.
- Harper JC (2008) Evaluating hyperandrogenism: a challenge in acne management. *J Drugs Dermatol* 7: 527-530.
- Kurokawa I, Danby FW, Ju Q, Wang X, Xiang LF, et al. (2009) New developments in our understanding of acne pathogenesis and treatment. *Exp Dermatol* 18: 821-832.
- Lai JJ, Chang P, Lai KP, Chen L, Chang C (2012) The role of androgen and androgen receptor in skin-related disorders. *Arch Dermatol Res* 304: 499- 510.
- Lolis MS, Bowe WP, Shalita AR (2009) Acne and systemic disease. *Med Clin North Am* 93: 1161-1181.
- Lucky AW, Biro FM, Huster GA, Leach AD, Morrison JA, et al. (1994) Acne vulgaris in premenarchal girls. An early sign of puberty associated with rising levels of dehydroepiandrosterone. *Arch Dermatol* 130: 308-314.
- Chen MJ, Chen CD, Yang JH, Chen CL, Ho HN, et al. (2011) High serum dehydroepiandrosterone sulfate is associated with phenotypic acne and a reduced risk of abdominal obesity in women with polycystic ovary syndrome. *Human Reprod* 26: 227-234.
- Lucky AW (1995) Hormonal correlates of acne and hirsutism. *Am J Med* 98: 89S-94S.
- Darley CR, Moore JW, Besser GM, Munro DD, Edwards CR, et al. (1984) Androgen status in women with late onset or persistent acne vulgaris. *Clin Exp Dermatol* 9: 28-35.
- Gollnick H, Cunliffe W, Berson D, Dreno B, Finlay A, et al. (2003) Management of acne. *J Am Acad Dermatol* 49: S1-S37.
- Stewart ME, Greenwood R, Cunliffe WJ, Strauss JS, Downing DT (1986) Effect of cyproterone acetate-ethinyl estradiol treatment on the proportions of linoleic and sebaleic acids in various skin surface lipid classes. *Arch Dermatol Res* 278: 481-485.
- Thiboutot DM (2001) Endocrinological evaluation and hormonal therapy for women with difficult acne. *J Eur Acad Dermatol Venereol* 15: 57-61.
- van Wayjen RG, van den Ende A (1995) Experience in the long-term treatment of patients with hirsutism and/or acne with cyproterone acetate- containing preparations: efficacy, metabolic and endocrine effects. *Exp Clin Endocrinol Diabetes* 103: 241-251.
- Gollnick H, Albring M, Brill K (1999) The effectiveness of oral cyproterone acetate in combination with ethinylestradiol in acne tarda of the facial type. *Ann Endocrinol (Paris)* 60: 157-166.
- Faure M, Drapier-Faure E (2003) Hormonal treatments of acne. *Ann Dermatol Venereol* 130: 142-147.
- Savidou I, Deutsch M, Soultati AS, Koudouras D, Kafiri G, et al. (2006) Hepatotoxicity induced by cyproterone acetate: a report of three cases. *World J Gastroenterol* 12: 7551-7555.
- Medicines and Healthcare products Regulatory Agency, Cyproterone acetate with ethinylestradiol (co-cyprindiol): balance of benefits and risks remains positive.
- Kim GK, Del Rosso JQ (2012) Oral spironolactone in post-teenage female patients with acne vulgaris: practical considerations for the clinician based on current data and clinical experience. *J Clin Aesthet Dermatol* 5: 37-50.
- Goodfellow A, Alagband-Zadeh J, Carter G, Cream JJ, Holland S, et al. (1984) Oral spironolactone improves acne vulgaris.

- is and reduces sebum excretion. *Br J Dermatol* 111: 209-214.
27. Burke BM, Cunliffe WJ (1985) Oral spironolactone therapy for female patients with acne, hirsutism or androgenic alopecia. *Br J Dermatol* 112: 124-125.
 28. Muhlemann MF, Carter GD, Cream JJ, Wise P (1986) Oral spironolactone: an effective treatment for acne vulgaris in women. *Br J Dermatol* 115: 227-232.
 29. Shaw JC (1991) Spironolactone in dermatologic therapy. *J Am Acad Dermatol* 24: 236-243.
 30. Burke BM, Cunliffe WJ (1985) Oral spironolactone therapy for female patients with acne, hirsutism or androgenic alopecia. *Br J Dermatol* 112: 124-125.
 31. Akamatsu H, Zouboulis CC, Orfanos CE (1993) Spironolactone directly inhibits proliferation of cultured human facial sebocytes and acts antagonistically to testosterone and 5-alpha-dihydrotestosterone in vitro. *J Invest Dermatol* 100: 660-662.
 32. Thiboutot D (2004) Acne: hormonal concepts and therapy. *Clin Dermatol* 22: 419-428.
 33. Brown J, Farquhar C, Lee O, Toomath R, Jepson RG (2009) Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne. *Cochrane Database Syst Rev* : CD000194.
 34. Plovanich M, Weng QY, Mostaghimi A (2015) Low Usefulness of Potassium Monitoring Among Healthy Young Women Taking Spironolactone for Acne. *JAMA Dermatol* 151: 941-944.
 35. Danielson DA, Jick H, Hunter JR, Stergachis A, Madsen S (1982) Nonestrogenic drugs and breast cancer. *Am J Epidemiol* 116: 329-332.
 36. Calaf J, López E, Millet A, Alcañiz J, Fortuny A, et al. (2007) Long-term efficacy and tolerability of flutamide combined with oral contraception in moderate to severe hirsutism: a 12-month, double-blind, parallel clinical trial. *J Clin Endocrinol Metab* 92: 3446-3452.
 37. Adalatkah H, Pourfarzi F, Sadeghi-Bazargani H (2011) Flutamide versus a cyproterone acetate-ethinyl estradiol combination in moderate acne: a pilot randomized clinical trial. *Clin Cosmet Investig Dermatol* 4: 117-121.
 38. Paradisi R, Fabbri R, Porcu E, Battaglia C, Seracchioli R, et al. (2011) Retrospective, observational study on the effects and tolerability of flutamide in a large population of patients with acne and seborrhea over a 15-year period. *Gynecol Endocrinol* 27: 823-829.
 39. Adalatkah H, Pourfarzi F, Sadeghi-Bazargani H (2011) Flutamide versus a cyproterone acetate-ethinyl estradiol combination in moderate acne: a pilot randomized clinical trial. *Clin Cosmet Investig Dermatol* 4: 117-121.
 40. Wang HS, Wang TH, Soong YK (1999) Low dose flutamide in the treatment of acne vulgaris in women with or without oligomenorrhea or amenorrhea. *Changcheng Yi XueZaZhi* 22: 423-432.
 41. Cusan L, Dupont A, Gomez JL, Tremblay RR, Labrie F (1994) Comparison of flutamide and spironolactone in the treatment of hirsutism: a randomized controlled trial. *Fertil Steril* 61: 281-287.
 42. Cusan L, Dupont A, Bélanger A, Tremblay RR, Manhes G, et al. (1990) Treatment of hirsutism with the pure antiandrogen flutamide. *J Am Acad Dermatol* 23: 462-469.
 43. Couzinet B, Pholsena M, Young J, Schaison G (1993) The impact of a pure anti-androgen (flutamide) on LH, FSH, androgens and clinical status in idiopathic hirsutism. *Clin Endocrinol (Oxf)* 39: 157-162.
 44. Motta T, Maggi G, Perra M, Azzolari E, Casazza S, et al. (1991) Flutamide in the treatment of hirsutism. *Int J Gynaecol Obstet* 36: 155-157.
 45. Pizzo A, Borrielli I, Mastroeni MT, Fattori A, Dugo C, et al. (2008) [Low-dose flutamide in the treatment of hyperandrogenism in adolescents]. *Minerva Pediatr* 60: 1357-1366.
 46. Nast A, Dréno B, Bettoli V, Degitz K, Erdmann R, et al. (2012) European evidence-based (S3) guidelines for the treatment of acne. *J Eur Acad Dermatol Venereol* 26: 1-29.